Expertise in
30
conditions

Dr. Andrew Sloan

Neurosurgery
Clinical Neuroscience Institute At Miami Valley Hospital
30 E Apple St Ste 5254, 
Dayton, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
30
conditions
Clinical Neuroscience Institute At Miami Valley Hospital
30 E Apple St Ste 5254, 
Dayton, OH 

Overview

Andrew Sloan is a Neurosurgery provider in Dayton, Ohio. Dr. Sloan is highly rated in 30 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Gamma Knife Radiosurgery. Dr. Sloan is currently accepting new patients.

His clinical research consists of co-authoring 185 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Neurosurgery

Licenses

Neurological Surgery in OH

Hospital Affiliations

Miami Valley Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Clinical Neuroscience Institute at Miami Valley Hospital
30 E Apple St Ste 5254, Dayton, OH 45409
Other Locations
Clinical Neuroscience Institute at Miami Valley Hospital South Campus
2300 Miami Valley Dr Ste 550, Centerville, OH 45459

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase II Trial O6-benzylguanine(BG) and Temozolomide(TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140K MGMT+Hematopoietic Progenitors to Protect Hematopoiesis
Phase II Trial O6-benzylguanine(BG) and Temozolomide(TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140K MGMT+Hematopoietic Progenitors to Protect Hematopoiesis
Enrollment Status: Recruiting
Publish Date: November 21, 2025
Intervention Type: Radiation, Drug, Biological
Study Drugs: P140K-MGMT, O6-benzylguanine, Temozolomide, Filgrastim, Carmustine
Study Phase: Phase 2
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Combination product, Procedure, Drug
Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide
Study Phase: Phase 2
Phase I/II Study of Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Phase I/II Study of Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2026
Intervention Type: Procedure, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 1/Phase 2
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Biological, Drug
Study Drug: Oncolytic Polio/Rhinovirus Recombinant Vaccine
Study Phase: Phase 2
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Biological
Study Drugs: PVSRIPO, Pembrolizumab
Study Phase: Phase 2
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Device
A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Biological, Device, Other
Study Phase: Phase 2
06-benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) in Patients With MGMT Positive Tumors With Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis
06-benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) in Patients With MGMT Positive Tumors With Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Biological, Procedure, Other, Radiation, Drug
Study Drugs: MGMTP140K-encoding retroviral vector, O6-benzylguanine, Temozolomide
Study Phase: Phase 1
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

185 Total Publications

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.
Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas.
Journal: bioRxiv : the preprint server for biology
Published: August 12, 2025
Similar Doctors
Ronald E. Warnick
Expertise in
31
conditions
Dr. Ronald E. Warnick
Neurosurgery
Expertise in
31
conditions
Dr. Ronald E. Warnick
Neurosurgery

Mayfield Brain & Spine

55 Pinnacle Point Drive, 
Miamisburg, OH 
 (9.3 miles away)
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Warnick, MD is a neurosurgeon practicing at TriHealth. Dr. Warnick is highly rated in 31 conditions, according to our data. His top areas of expertise are Meningioma, Posterior Fossa Tumor, Trigeminal Neuralgia, Gamma Knife Radiosurgery, and Endovascular Embolization.

Expertise in
25
conditions
Dr. Francesco Mangano
Neurosurgery
Expertise in
25
conditions
Dr. Francesco Mangano
Neurosurgery

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (45.0 miles away)
513-636-4726
Languages Spoken:
English
See accepted insurances

Francesco Mangano is a Neurosurgery provider in Cincinnati, Ohio. Dr. Mangano is highly rated in 25 conditions, according to our data. His top areas of expertise are Hydrocephalus, Cortical Dysplasia, Epilepsy, Posterior Fossa Decompression, and Laminectomy.

Expertise in
17
conditions
Dr. Owoicho Adogwa
Neurosurgery
Expertise in
17
conditions
Dr. Owoicho Adogwa
Neurosurgery

University Of Cincinnati Physicians Company LLC

3113 Bellevue Ave, 
Cincinnati, OH 
 (45.4 miles away)
513-475-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Owoicho Adogwa is a Neurosurgery provider in Cincinnati, Ohio. Dr. Adogwa is highly rated in 17 conditions, according to our data. His top areas of expertise are Spondylolisthesis, Spinal Stenosis, Scoliosis, Spinal Fusion, and Laminectomy. Dr. Adogwa is currently accepting new patients.

Frequently Asked Questions about Dr. Andrew Sloan

How do I make an appointment with Dr. Andrew Sloan?

You can book an appointment with Dr. Andrew Sloan by calling their office at 937-345-3797. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew Sloan a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew Sloan is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew Sloan specialize in?

While Dr. Andrew Sloan is a Neurosurgery, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurosurgery.

Does Dr. Andrew Sloan participate in research or clinical trials?

Yes. Dr. Andrew Sloan has published 185 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Andrew Sloan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew Sloan accept my insurance?

Dr. Andrew Sloan accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 937-345-3797 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sloan's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 9 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile